Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insuranceGlobeNewsWire • 03/16/23
Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma AcquisitionsZacks Investment Research • 03/13/23
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash dealProactive Investors • 03/13/23
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi DealInvestors Business Daily • 03/13/23
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)GlobeNewsWire • 03/13/23
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV RaceInvestors Business Daily • 03/08/23
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA reviewGlobeNewsWire • 03/07/23
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA ApprovalThe Motley Fool • 03/06/23
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of childrenGlobeNewsWire • 03/02/23
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)GlobeNewsWire • 02/24/23
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe diseaseGlobeNewsWire • 02/24/23
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protectionGlobeNewsWire • 02/23/23